Novo Nordisk stock lines up 26 ObesityWeek presentations

Published on 10/30/2026 at 15:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock will feature new obesity findings in November. The program covers CagriSema, Wegovy treatment experience and pediatric research.

November Brings Several Obesity Catalysts

Novo Nordisk will present new findings on CagriSema, Wegovy and pediatric semaglutide research.
Real-world treatment experience and telehealth analyses broaden the planned obesity-care program.
The November schedule gives investors several clinical checkpoints before the company's next financial update.

Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

Novo Nordisk will present new findings from its obesity portfolio at ObesityWeek 2026, expanding the company's near-term pipeline calendar. A PR Newswire release carried by Yahoo Finance said on October 29 that the program includes 26 abstracts at the Washington, D.C., meeting from November 14 to 17.

What The Presentations Will Cover

The program spans investigational CagriSema, oral and injectable Wegovy, and semaglutide injection research in children aged 6 to under 12. Planned CagriSema material includes primary results from the lower-dose REDEFINE 9 study and additional analyses from REDEFINE 1.

The Wegovy work focuses on treatment experience in routine care, including telehealth studies of oral semaglutide and injection treatment. The company also plans presentations on food noise, patient-reported outcomes, medication preferences and a digital support program.

Pipeline Signal Before Results

The announcement sets out a future presentation schedule rather than reporting new trial outcomes. CagriSema remains investigational and is not approved in the United States or elsewhere, while investigational semaglutide injection is not approved in the United States for children under 12.

This creates a series of clinical checkpoints for investors, but the eventual investment significance will depend on the findings presented and how they compare with competing obesity treatments. The new program broadens the focus from recent analyst target changes and second-quarter figures to upcoming evidence across development and real-world use.

The real-time quote of Novo Nordisk stock was 35.67 euros on Lang & Schwarz at 15:35 CEST on Friday, October 30, 2026, 2.18 percent above the Xetra close of Thursday, October 29.